A Review of Inhaled Corticosteroid-Containing Agents and Tiotropium Prescribing Patterns for Chronic Obstructive Pulmonary Disease at Surrey Memorial Hospital

Qiong Wu, B.Sc. (Pharm)., Pharm.D.; Krystin Boyce, B.Sc. (Pharm)., ACPR; Emma Attfield, B.Sc. (Pharm)., ACPR; Nina Bredenkamp, B.Sc. (Pharm)., ACPR; Warren Davidson, M.D., FRCPC, M.HSc., FCCP; Giuseppe Giustino, M.D.; Joshua Song, M.D.; Denise Werry, B.Sc. (Pharm)., ACPR, Pharm.D.

Background	Table 1: Patient Characteristics (N=100)	
Studies reviewing chronic obstructive pulmonary disease (COPD) prescribing	Male, %	53
patterns have found non-concordance between clinical practice and the Global	Age (years), median (IQR)	74 (15.2)
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, such as:	Smoking Status, %	
Underuse of bronchodilator therapy	Current smoker	32
Overuse of inhaled corticosteroid-containing agents (ICS)	Former smoker	37
Concerns regarding the initiation of maintenance inhalers (e.g. ICS, tiotropium) on	Non-smoker	19
admission include:	Unclear/Not documented	12
Prescription based on a clinical diagnosis without confirmatory spirometry and/or appropriate follow, up	Smoking History (pack-years), median (IQR)	42.5 (25)
appropriate follow-up Compliance concerns due to the cost of inhalers in the community 	GOLD Stage, %	
 Adverse effects, e.g. increased risk of pneumonia in COPD patients receiving ICS 	Stage 1	1
	Stage 2	11
Objectives	Stage 3	8
Purpose: To relate the current prescribing patterns of ICS and tiotropium at Surrey	Stage 4	L CO
Memorial Hospital (SMH) to the GOLD 2019 guidelines to identify potential gaps in	Unable to stage Not applicable ⁺	58 21
inpatient COPD management and provide recommendations to optimize therapy		<u>۲</u> ک
Primary Objectives	GOLD Group*, % Group A/B	59
To describe patients newly initiated on ICS and/or tiotropium for COPD management	Group B	5
during hospital admission and characterize them into 4 groups:	Group C/D	6
Documented spirometry confirming COPD diagnosis	Group D	9
 Documented pre-existing COPD history without spirometry confirmation 	Not applicable ⁺	21
 New clinical COPD diagnosis during the index admission Prescribed inhalers for other reasons 	Patients with ≥ 1 prior exacerbation requiring hospitalization, %	13
Secondary Objectives	Patients with previous inhaler trials, %	
To describe guideline non-concordance based on the GOLD 2019 guidelines ¹	SABA	53
≥ 2 moderate Group C Group D	SADA	44
exacerbations or ≥ 1 leading to hospitalization LAMA LABA or ICS + LABA*	LAMA	5
10 or 1 moderate Group A *Consider if eosinophils ≥ 300	Combination LAMA/LABA	7
exacerbations (not leading to admission)	Patients with previous spirometry, %	44
$mMRC \ 0-1 \ or \ CAT < 10 \qquad mMRC \ge 2 \ or \ CAT \ge 10$	Patients with previous mMRC or CAT, %	14
To describe guideline non-concordance using the proportion of: Guideline non-concordant ICS discontinued prior to discharge Guideline non-concordant tiotropium discontinued prior to discharge	mMRC = modified Medical Research Council Dyspnea Scale; CAT = C * Unable to assess GOLD Groups A and C † No suspected or documented COPD	OPD Assessment Test
To describe the estimated retail cost of all guideline non-concordant prescriptions	Table 2: Details of Guideline Non-Concordant Inhalers	
Methods	Proportion of patients prescribed tiotropium without a trial of a SABA or SAMA in GOLD Group A	Unable to assess
 Design: Retrospective chart review of patients newly prescribed ICS and/or tiotropium during admission at SMH from January 2019 to August 2019 inclusive 	Proportion of patients prescribed ICS in GOLD Groups A, B, and C (n=49)*	93.9%
 Inclusion Criteria: Adult patients ≥ 18 years of age Received ICS and/or tiotropium during admission to SMH 	Proportion of patients prescribed ICS in GOLD Group D without a previous exacerbation on LAMA or LABA (n=9)	11.1%
 Exclusion Criteria: Prescribed ICS in hospital and receiving any ICS prior to admission Prescribed tiotropium in hospital and receiving any LAMA prior to admission Documented diagnosis of asthma or asthma/COPD overlap Discharged from hospital directly from critical care or surgical wards 	Proportion of guideline non-concordant ICS prescriptions discontinued prior to discharge (n=79)	26.6%
	Proportion of guideline non-concordant tiotropium prescriptions discontinued prior to discharge (n=5) ⁺	60.0%
	Estimated retail cost of all guideline non-concordant prescriptions during hospitalization	\$9647
 Sample: Convenience sample size of 100 patients selected in reverse chronological order from August 2019 for review 		
fraserhealth Vancouver	widence Provincial Health Services Authority	

HEALTH CARE

How you want to be treated










Figure 1: Characterization of Patients Newly Initiated on ICS and/or Tiotropium

- fluticasone/salmeterol, 5% fluticasone) and 24% received tiotropium

Retrospective design

- Unable to describe guideline non-concordance in GOLD Groups A and C as functional status scores (i.e. modified Medical Research Council Dyspnea Scale, COPD Assessment Test) were unavailable; these patients were instead classified as Group A/B or C/D
- Did not capture COPD exacerbations outside of Fraser Health, which could affect GOLD group classification and consequently whether therapy was guideline concordant
- Did not capture spirometry completed outside of Fraser Health, which could affect GOLD staging and characterization, i.e. confirmed COPD diagnosis with spirometry
- Medication reconciliation records only capture the 6 months prior to admission; previous inhaler trials may not have been fully summarized, and physician samples may not have been documented

discontinued prior to discharge

- Consistent documentation (i.e. functional status scores, exacerbation history, spirometry) would improve the ability to group and/or stage patients with COPD, and facilitate the assessment of guideline concordance in research and clinical practice
- Recommendations for optimizing COPD management include increasing referrals to outpatient diagnostic and chronic management services, and reassessing all inhaled medications during admission and transitions of care



Results

• Of the 21 patients who were prescribed inhalers for other reasons, all received an ICS (95%)

• 36% of patients with a new clinical COPD diagnosis were referred to outpatient services at discharge (e.g. Community Respiratory Services, pulmonary function testing, respirologist)

Limitations

Conclusions

The majority of patients in GOLD groups A, B, and C were prescribed guideline nonconcordant ICS, and only one-quarter of all guideline non-concordant ICS prescriptions were

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]; 2019 [cited 2020 Jun 1]. Available from: http://wwwgoldcopdorg/.